Fortrea is a leveraged CRO turnaround where backlog stability, cost cuts, and margin recovery could unlock asymmetric upside—but execution, debt, and customer concentration remain decisive risks.
Overview
Fortrea is a global CRO newly refocused as a pure-play Phase I-IV clinical-services provider after its Labcorp spin-off and 2024 Enabling Services divestiture. The company operates in 90+ countries with ~18,000 employees, serving pharma, biotech, and medical device sponsors. Its model combines high-margin clinical service fees with low-margin pass-through revenue. The investment case centers on whether Fortrea can convert its global scale, oncology exposure, backlog visibility, and AI-enabled FIT platform into sustained bookings, margin expansion, and deleveraging.